Organogenesis (NASDAQ:ORGO) Stock Price Up 9.5% - Time to Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s share price was up 9.5% during mid-day trading on Monday . The company traded as high as $5.22 and last traded at $5.35. 713,477 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 1,084,962 shares. The stock had previously closed at $4.88.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lifted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Trading Down 3.6 %

The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a 50-day moving average of $4.19 and a 200-day moving average of $3.56. The firm has a market capitalization of $570.73 million, a P/E ratio of -75.00 and a beta of 1.66.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 36.90% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC bought a new stake in shares of Organogenesis in the 3rd quarter worth approximately $43,000. Charles Schwab Investment Management Inc. boosted its holdings in Organogenesis by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company's stock valued at $2,713,000 after acquiring an additional 23,675 shares in the last quarter. FMR LLC increased its position in Organogenesis by 34.2% during the 3rd quarter. FMR LLC now owns 173,595 shares of the company's stock valued at $496,000 after purchasing an additional 44,199 shares during the period. Captrust Financial Advisors bought a new position in Organogenesis in the 3rd quarter worth $36,000. Finally, Verition Fund Management LLC lifted its position in shares of Organogenesis by 542.8% in the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company's stock worth $225,000 after purchasing an additional 66,448 shares during the period. Hedge funds and other institutional investors own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.